A B S T R A C T When blood is clotted, a2-plasmin inhibitor (a2PI) is cross-linked to fibrin by activated fibrin-stabilizing factor (activated coagulation Factor XIII, plasma transglutaminase). The amount of crosslinked a2-PI is proportional to the amount of a2PI present at the time of clotting. Plasma from a patient with congenital deficiency of a2PI was supplemented with various amounts of purified a2PI. Clots were prepared from these plasmas and were suspended in plasma containing a normal concentration of a2PI, and spontaneous clot lysis was observed. When the clot was formed in the presence of calcium ions and thereby allowing cross-linking to occur, the rate and extent of fibrinolysis were found to be inversely proportional to the concentrations of a2PI present in the clot at the time of clotting. When the clot was formed in the absence of calcium ions so that no cross-linking occurred, the clot underwent fibrinolysis at similar rates, regardless of the concentrations of a2PI in the clot. When the clot formed in the presence of calcium ions was squeezed and washed to remove unbound proteins before being suspended in plasma, the extent of fibrinolysis was also inversely proportional to the amount of a2PI cross-linked to fibrin. Similar results were obtained when the clot was suspended in buffered saline instead of plasma. These observations suggest that spontaneous fibrinolysis is mainly carried out by plasminogen/plasminogen activator bound to fibrin, and this fibrinolysis caused by fibrin-associated activation of plasminogen was mainly inhibited by a2PI crosslinked to fibrin. To further support this concept, a2PI treated with activated fibrin-stabilizing factor and that had lost most of its cross-linking capacity was used in similar experiments. This modified a2PI had the same inhibitory activity on plasmin as the native inhibitor, but gave significantly less inhibition of fibrinolysis in
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The concentration of a2PI in the circulating blood is readily reduced when plasminogen is activated under thrombolytic therapy or in disseminated intravascular coagulation, because a2PI rapidly inhibits plasmin evolved by forming a complex, and the complex is removed from the circulating blood by the reticuloendothelial system (9) (10) (11) .
In addition to the rapid inactivation of plasmin, a2PI interferes with adsorption of plasminogen to fi-brin, resulting in an efficient inhibition of fibrinolysis (13) . Furthermore, a2PI is cross-linked to fibrin when blood is clotted, thereby making the fibrin clot less susceptible to lysis by plasmin (2) . The cross-linking is catalyzed by activated fibrin-stabilizing factor (activated FSF, fibrinoligase, blood coagulation Factor XIIIa, plasma transglutaminase), and the amount of a2PI cross-linked to fibrin is dependent on the concentrations of activated FSF (FSFa), fibrin, and a2PI (2) . Reduced resistance of a plasma fibrin clot prepared from FSF-deficient plasma to plasmin-catalyzed fibrinolysis may be, at least partially, accounted for by the lack of a2PI cross-linking in FSF-deficient plasma. It is also known that another plasma component called plasma fibronectin is cross-linked to fibrin when blood is clotted (14) . The cross-linking is also catalyzed by FSFa. However, cross-linking of a2PI to fibrin occurs independently of fibronectin cross-linking, and the presence or absence of plasma fibronectin does not influence the rate and extent of a2PI cross-linking to fibrin (15) .
The purpose of this paper is to demonstrate the significance of a2PI cross-linking to fibrin in inhibition of fibrinolysis and infer from this information its meaning in hemostasis.
METHODS
Plasma. Blood was collected from antecubital veins of normal subjects or a patient with congenital deficiency of a2PI (12) into 0.1 vol of 3.8% sodium citrate, and it was centrifuged at 2,000 g for 20 min to prepare platelet-poor plasma. To obtain platelet-rich plasma, the citrated blood was centrifuged at 650 g for 4 min. Plasma was used for the experiments within 30 min after drawing the blood. Venipuncture in the patient and in normal subjects was performed after informed consent for the procedure was obtained. Proteins a2PI. a2PI was purified by the previously described method (1). The concentration was determined spectrophotometrically using absorbance All = 7.03 at 280 nm (1) . The protein was dissolved in Tris-buffered saline (0.05 M Tris-HCI, 0.15 M NaCl, pH 7.4).
Fibrinogen. Human fraction I-4 prepared according to the method of Blombiick and Blomback (16) was used as the fibrinogen preparation after removing contaminating plasminogen using lysine-Sepharose (17) . The concentration was determined spectrophotometrically using A", = 15.1 (16) (21), and was stored as a 600 U/ml solution in 50% glycerol at -20°C. Hirudin. The hirudin (a thrombin inhibitor obtained from leeches) used was a grade IV preparation from the Sigma Chemical Co., St. Louis, Mo., and was demonstrated to have no plasmin inhibitor activity when tested by the chromogenic (22) and the clot lysis (9) methods.
FSF. Purified FSF was prepared from human plasma by the described method (23) . The concentration of purified FSF was determined by measuring the absorbance of the FSF solution at 280 nm and converting absorbance to protein concentration using an extinction coefficient E"' = 13.8 for pure FSF (24) . FSF activity was assayed by an antibody neutralization method (25) using the clotting Factor XIII test kit supplied by Behringwerke AG, Marburg, Germany. 1 unit of FSF is defined as the amount of FSF present in 1 ml of normal pooled standard plasma, and the specific activity of the purified FSF was 40 U/mg protein. Thrombinmodified FSF was prepared by incubating purified FSF (2 mg/ml) with thrombin (5 U/ml) in Tris-buffered saline at 25°C for 30 min. Subsequently the mixture was mixed with 3 mM diisopropyl fluorophosphate (Sigma Chemical Co.) to inactivate thrombin, incubated further for 60 min at 25°C, and then dialyzed against 0.05 M Tris-HCl buffer, pH 7.4, containing 1 mM EDTA, at 4°C for 24 h. The preparation was stable at 4°C for at least a week. Thrombin-modified FSF thus obtained was converted to active FSF by calcium ions added at the time of the experiments.
FSF-treated a2PI. a2PI (600 ug/iml) was incubated with thrombin-modified FSF (25 Mg/ml) and calcium chloride (5 mM) in Tris-buffered saline for 8 h at 25°C. The a2PI thus treated and the original a2PI were separately iodinated with 125I, and both were tested for their susceptibility to FSF-catalyzed cross-linking with fibrin as previously described (2). When 2.5 mg/ml of fibrinogen was used, 34% of native a2PI and 5% of FSF-treated a2PI were cross-linked to fibrin, indicating that FSF-treated a2PI had lost most of its susceptibility to the FSF-catalyzed cross-linking reaction and retained only 15% of the cross-linking capacity of normal a2PI. The other two functional properties other than crosslinking capacity namely, the immediate inhibition of plasmin (1) , and the interference with the binding of plasminogen to fibrin (13, 26) , were totally intact in FSFtreated a2PI.
Plasminogen activation during the spontaneous clot lysis. Plasminogen activation during spontaneous clot lysis was followed by measuring amidolytic activity generated and by observing the distribution of radioactivity in SDS gel electrophoresis of the labeled plasminogen added to plasma before clotting. 100-,ul aliquots of a2PI-deficient fresh plateletpoor plasma or normal plasma was mixed with 3 p.l of the radiolabeled plasminogen, 3 sul of calcium chloride (0.05 M), and 5 Mul of thrombin (40 U/ml). The clot formed was in-cubated at 37°C. For amidolytic assay, 192 Al of Tris-buffered saline and 700 M1 of 3 mM H-D-valyl-leucyl-lysinyl-pnitroaniline (a chromogenic substrate for plasmin, S-2251) (Kabi Diagnostica, Stockholm, Sweden) were added to the clot after various lengths of time. The clot was immediately squeezed with a bamboo stick to express as much fluid as possible from the clot. The mixture containing the suspended clot was further incubated at 37°C. 3 min after the addition of S-2251, 100 Al of 50% acetic acid was added and mixed to stop the reaction. Absorbance of the liquid phase at 405 nm was measured, and the amidolytic activity on S-2251 was expressed as nanokatals per milliliter of original mixture using an absorbance value of 10.5 at 405 nm for 1 mM pnitroaniline. As a blank, acetic acid was added to the clot at the time of addition of S-2251. For the observation of distribution of radioactivity in SDS gel electrophoresis, 900
Ml of 10 M urea/10% SDS/10% 2-mercaptoethanol solution were added to the clot after various lengths of time and immediately heated in a boiling water for 30 min to obtain the solubilized sample. The sample was mixed with 25 Ml of 50% glycerol and then subjected to SDS polyacrylamide gel electrophoresis on 5% polyacrylamide gel (20) . After fixing with 50% methanol/10% acetic acid mixture, the gel was cut into slices of 1-mm thickness using gel slicer HP 100 (Hotta Rika, Tokyo). Each sliced gel was counted for radioactivity. Plasminogen activation was also assessed by comparing plasminogen activity in plasma before clotting with that in serum after complete lysis of the clot. Plasminogen activity was assayed by the caseinolytic method (27) .
Spontaneousin vitro fibrinolysis. 5 ml of a2PI-deficient fresh platelet-poor plasma was mixed with 10 Ml of radiolabeled fibrinogen. 200 ,l of the mixture was mixed with 10 IAl of a2PI of various concentrations or buffered saline. Each of these mixtures was clotted with 10 Ml of thrombin (50 U/ ml) containing 0.5 M calcium chloride or 0.06 M EDTA. After incubation at 370C for 30 min, the clot formed was suspended in 1 ml of fresh normal plasma containing 2.5 mM EDTA and 1 unit of hirudin, and was further incubated at 37°C for as long as 24 h. The purposes of including EDTA and hirudin in the suspending plasma milieu were to prevent the suspending plasma from being clotted by thrombin or gelated by activated FSF released from the clot. In some experiments, the clot was first squeezed with a bamboo stick against the wall of the tube to express as much fluid as possible, washed three times by soaking it in 2 ml of Tris-buffered saline containing 2% of albumin for 5 min at room temperature each time, and then finally suspended in 1 ml of plasma or buffered saline containing 2% albumin. To measure fibrinolysis, 25-,l aliquots of the suspending plasma or buffered saline were removed at intervals for counting of radioactivity. Results were expressed as the percent release of radiolabel, which was calculated from the counts, applying a correction for the influence of repeated subsampling upon the volume of the supernatant. In other experiments, the clot formed was simply left in the tube without being suspended in plasma. After various lengths of incubation, the clot was squeezed and 25 Ml of the liquid phase was counted for radioactivity. Radioactivity was counted using the Auto-Well gamma system, Aloka ARC-451 (Aloka Co., Tokyo, Japan).
RESULTS
Plasminogen activation during spontaneous clot lysis. When the a2PI-deficient fresh plasma clot was incubated at 37°C, the clot was spontaneously lysed after several hours. Plasmin generation during the spontaneous clot lysis was followed by assaying for amidolytic activity and by SDS gel electrophoresis using radiolabeled plasminogen. There was a small amidolytic activity towards S-2251 in plasma before clotting, and this activity was not increased for the1st h of incubation after clotting (Fig. 1) . During this period of time, the peak of radioactivity was not changed and there was no appearance of a new peak of radioactivity in SDS gel electrophoresis. After this lag time, there was an appearance of a new distinct peak of radioactivity with a concomitant rise of amidolytic activity. The new peak of radioactivity corresponded to the light chain of plasmin. The peak of the heavy chain was partly buried in the slope of the large peak of plasminogen. Any other peak suggestive of the formation of plasmin-inhibitor complex was not detected. The height of the peak of the light chain and amidolytic activity rapidly increased and reached plateau levels after an -8-h incubation, when the clot was completely lysed (Fig. 1) .
Plasminogen activities of the plasma samples before clotting were 2.4±0.15 U/ml (n = 5), whereas those of the serum samples (clotted and lysed samples) were 2.15±0.07 U/ml (n = 5). The difference was significant (P <0.02) and -10% of the average plasminogen activity of the plasma samples. Since plasminogen concentration in the plasma was -2 MM (12), plasmin generated during the clot lysis was calculated to be -0.2 uM. When normal plasma was clotted and incubated, no fibrinolysis was observed and there was neither appearance of the light chain nor rise of amidolytic activity ( Fig. 1) because any plasmin generated would have been immediately neutralized by a2PI.
Spontaneous fibrinolysis of the clot suspended in plasma or buffered saline. When the fresh plasma clots containing various subnormal concentrations of a2PI were suspended in fresh plasma, remarkable fibrinolysis occurred in spite of the presence of a normal concentration of a2PI in the suspending plasma milieu. The rate of fibrinolysis, however, was dependent on whether calcium ions were present or not at the time of clotting. When calcium ions were present, FSF-catalyzed cross-linking occurred, and the rate of fibrinolysis was inversely related to the concentration of a2PI present at the time of clotting (Fig. 2) . When calcium ions were absent, FSF-catalyzed cross-linking did not occur and the rate of fibrinolysis was accelerated. Furthermore, the rate of fibrinolysis became less dependent on the a2PI concentration in the clotting plasma (Fig. 2) .
To determine if the dependence of the lysis rate of cross-linked fibrin on a2PI concentration in the clotting plasma was due to the difference in the amount of a2PI bound to fibrin, the clot formed in the presence of calcium ions was squeezed and washed to remove proteins unbound to fibrin before suspending the clot in plasma. The results obtained were similar to those of cross-linked fibrin in Fig. 2 and demonstrated again that fibrinolysis was inhibited in proportion to the a2PI concentration in the clotting plasma at the time of clotting. Omission of the washing procedure (the clot was only squeezed before being suspended in plasma) did not appreciably affect the results.
When the clots formed in the presence of calcium ions were squeezed, washed, and suspended in buffered saline instead of plasma, fibrinolysis was still observed; and inhibition of fibrinolysis was similarly dependent on the a2PI concentration in the clotting plasma (Fig. 3) .
Effects of FSF-treated a2PI on fibrinolysis. To further determine the effect of cross-linking of a2PI to fibrin on the lysis rate, FSF-treated a2PI that had lost nearly 85% of its cross-linking capacity but fully maintained all the other functions was used and compared with the native a2PI in the same experiments as those described above in the presence of calcium ions. FSF-treated a2PI gave less inhibition of fibrinolysis under both experimental conditions, with and without washing of the clot. When the clot was not washed, the dependence of inhibition of fibrinolysis on a2PI concentration in the clotting plasma was still seen with FSF-treated a2PI, although inhibition of fibrinolysis became less. When the clot was squeezed -----------. 150 15 30 60 a2PI (Pg/mi) FIGURE 2 Spontaneous in vitro fibrinolysis of plasma clots suspended in plasma. Citrated platelet-poor plasma containing radiolabeled fibrinogen and various amounts of a2PI was clotted by thrombin in the presence (solid line) or the absence (broken line) of calcium ions. The clot formed was suspended in normal plasma and incubated at 370C. At 2 (-), 6 (0), and 24 (A) h of incubation, release of radiolabel from the clot into the suspending plasma milieu was measured and expressed as a percentage of the total radioactivity. The concentrations of a2PI in the clot at the time of clotting are given on the abscissa. (Methods).
and washed, FSF-treated a2PI gave markedly less inhibition of fibrinolysis; and the difference of inhibition as a result of the different amount of a2PI present in the clotting plasma became very small and was seen only during the early period of fibrinolysis (Fig. 4) . Platelet-rich or poor plasma, containing 50% of the normal concentration of native or FSF-treated a2PI, was clotted in the presence of calcium ions, and incubated at 37°C. The platelet-rich plasma clot was retracted maximally within 2 h. When native a2PI was used, platelet-rich plasma clot underwent only slightly more accelerated fibrinolysis than the platelet-poor plasma clot (Fig. 5) . When FSF-treated a2PI was used, however, the difference became pronounced and remarkably enhanced fibrinolysis was observed with the platelet-rich plasma clot (Fig. 5) .
DISCUSSION
When a2PI-deficient plasma obtained from a patient with congenital deficiency of a2PI (12) was clotted and incubated at 370C, the clot underwent spontaneous lysis, and complete lysis was observed after several hours of incubation (12, 28) . In this study, even when the clot was squeezed, washed to remove unbound protein, and suspended in buffered saline, the clot still underwent spontaneous lysis. This indicates that spontaneous fibrinolysis was carried out by plasminogen/ plasminogen activators bound to fibrin during the clot formation.
When the clot was suspended in normal plasma containing a normal concentration of a2PI, the clot still underwent spontaneous lysis. Clot lysis was complete at 8-24 h of incubation in spite of a sufficient amount of a2PI (-1 ,uM) in the suspending plasma milieu to neutralize plasmin generated (n0.2 ,uM) during clot lysis. Since no appreciable generation of amidolytic activity and no formation of plasmin light chain that contains active site were observed during the 1st h of clot incubation (Fig. 1) , plasmin responsible for lysis of the clot must have been generated in the clot while the clot was being suspended in the plasma milieu, but not during the initial 30 min alloted for clot formation before suspension in plasma. Thus, fibrinolysis carried out by plasmin generated while the clot was being suspended in plasma was not appreciably affected by a2PI present in the surrounding plasma milieu.
When a2PI-deficient plasma was supplemented with various amounts of a2PI and then clotted in the presence of calcium ions, fibrinolysis was inhibited in proportion to the amounts of a2PI present in the clotting plasma (Figs. 2 and 3 ). Since the amount of a2PI crosslinked to fibrin is directly proportional to the concentrations of a2PI present in the clot at the time of clotting (2, 15) , it can be said that inhibition of fibrinolysis is dependent on the amounts of a2PI cross-linked to fibrin. The cross-linking reaction of a2PI to fibrin is very rapid and complete within a few minutes at 370C (15) . Therefore, the period of 30 min alloted for clot formation in the present studies was considered to be long enough to allow the maximum cross-linking of a2PI, in addition to the complete y-cross-linking and the partial a-cross-linking of fibrin. In the absence of calcium ions, so that no cross-linking can occur, fibrinolysis was accelerated and a2PI-dependent inhibition of fibrinolysis became virtually ineffective (Fig. 2) .
From these results, it may be suggested that spontaneous fibrinolysis that is the result of the fibrin-associated process of plasminogen activation is mainly inhibited by a2PI cross-linked to fibrin. If this is true, a2PI, which is only devoid of the cross-linking capacity but maintains all its other functions, should give considerably less inhibition of fibrinolysis. To examine this possibility, FSF-treated a2PI was used. Treatment of the protein with activated FSF causes an irreversible hydrolysis of the y-carboxamide group of the glutamine residue susceptible to the action of activated FSF (29) , resulting in a loss of -85% of the cross-linking capacity of a2PI. When this FSF-treated a2PI was used in the experiments, a markedly less inhibition of fibrinolysis was observed, particularly when the squeezed clots were suspended in plasma (Fig. 4) .
In in vivo thrombus formation, platelets are involved and clot retraction takes place. Since clot retraction has a similar effect produced by squeezing the clot, the present studies using a squeezed clot may be regarded as a simulation of clot retraction. Therefore, platelet-rich a2PI-deficient plasma supplemented with native or FSF-treated a2PI was clotted in the presence of calcium ions, and its spontaneous fibrinolysis was compared with that obtained with platelet-poor plasma. The results indicated that decreases in inhibition of fibrinolysis with FSF-treated a2PI was more pronounced in the platelet-rich plasma clot than that in the platelet-poor plasma clot (Fig. 5) . In other words, inhibitory activity of FSF-treated a2PI on fibrinolysis was minimized when clot retraction took place, because the most of FSF-treated a2PI was not bound to fibrin and squeezed out from the clot when the clot was retracted. This emphasizes that cross-linked a2PI plays more important role in inhibition of spontaneous lysis of retracted clot than in inhibition of spontaneous lysis of nonretracted clot.
It is interesting to note that the amount of crosslinked a2PI is -0.2 ,mol/liter plasma when normal plasma is clotted (2) , and this amount is nearly equivalent to the amount of plasmin generated during the spontaneous lysis of an ax2PI-deficient plasma clot. Because of this, usually no fibrinolysis is observed when a normal plasma clot is incubated. All these experimental results suggest that spontaneous fibrinolysis is mainly caused by fibrin-associated plasminogen activation (activation of fibrin-bound plasminogen by fibrin-bound plasminogen activator), and effectively inhibited by a2PI cross-linked to fibrin. The absence of Ca2PI cross-linking to fibrin (2) may largely contribute to an accelerated fibrinolysis of hemostatic plugs and bring about hemorrhagic diathesis in patients with congenital deficiency of FSF.
